Was Buffett Wrong About This Blue Chip?

By Max Macaluso, Brenton Flynn, and Dave Williamson – Dec 20, 2012 at 6:30PM

NYSE: JNJ

Johnson & Johnson

Market Cap

$361B

Today's Change

(0.04%) $0.06

Current Price

$149.91

Price as of May 10, 2024, 4:00 p.m. ET

Is holding on to all of Merck's departments the right move?

Our health care roundtable gathers The Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.

In this portion of the video, our guys discuss Warren Buffett's latest portfolio moves in the health care industry. They also continue debate regarding the merits of spinning off businesses, such as Abbott Labs' (ABT 0.07%) spinoff of Abbvie as of the first of next year. They take a look at Merck (MRK -0.13%) and Johnson & Johnson (JNJ 0.04%), two companies sticking by the conglomerate model and retaining all of their businesses, and they explore if they think it's the right approach.

Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Berkshire Hathaway. The Motley Fool owns shares of Berkshire Hathaway, International Business Machines, and Johnson & Johnson. Motley Fool newsletter services recommend Berkshire Hathaway, International Business Machines, and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.